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Abstract: The aim of this study was to determine the variability of
TD in children undergoing HSCT. Cases were identified as
consecutively enrolled children in the period January 2011–January
2013 among patients attending the Paediatric Department of Spedali
Civili of Brescia and all candidates to HSCT. The TST was
conducted in two phases: identification of threshold values and
identification of perceived stimulus intensity. Sixteen sapid solutions
with four flavors (sucrose, sodium chloride, citric acid, and quinine
hydrochloride) at four diﬀerent concentrations were administered in
a random sequence. The same protocol was administered at diﬀerent
time intervals: before starting the conditioning therapy (T0), during
the conditioning therapy (T1) (two times), and every three months
(two times) after engraftment post-HSCT (T2). A p-value < 0.05
was considered statistically significant. Fifty-one children (29 female
and 22 male, mean age 5.2 ! 0.7 yr) were enrolled. Threshold value
means for the four flavors increased during HSCT conditioning
therapy (T1) (p < 0.01); intensity of perceived stimulus decreased
during HSCT conditioning therapy (p < 0.01). At six months after
engraftment (T2), both parameters had returned to starting values
(T0). Changes in taste perception in children undergoing HSCT
seem to occur especially during the conditioning therapy and resolve
in about six months after engraftment post-HSCT.
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While advances in cancer therapy for children
continue resulting in higher survival rate, oral
complications remain a significant cause of
morbidity and potential mortality. Cancer ther-
apy-related oral complications are common in
paediatric patients undergoing chemotherapy,
myeloablative chemotherapy prior to HSCT, or
radiation therapy for head and neck cancers or
solid tumors (1, 2). Children and adolescents
present with acute and long-term oral side eﬀects
more than adults with an incidence of 30–100%
(3, 4).
HSCT is widely used as a potentially curative
treatment for patients with various hematological
malignancies, bone marrow failure syndromes,
and congenital immune deficiencies. The course
and success of the transplant can be aﬀected by
oral complications, whose overall prevalence is
estimated to be 80% (5). Mucositis, oral infec-
tions, TD, xerostomia, and bleeding are recog-
nized as common acute oral complications with
risks of severe pain, malnutrition, and potential
systemic infections, resulting in increased hospital-
ization and higher costs of care (6, 7). Many stud-
ies have addressed oral mucositis and xerostomia,
while very few studies have been published on TD
in children.
The sense of taste is a sensorial system modal-
ity that has a critical role in the life and nutri-
tional status of the human being (8). It is
Abbreviations: HSCT, hematopoietic stem cell transplanta-
tion; TBI, total body irradiation; TD, taste dysfunction;
TST, taste sensitivity test.
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estimated that about 50–75% of cancer patients
suﬀer from TD, which could impact perception
for all four tastes, that is, salty, sweet, sour, and
bitter (9). The impaired ability to taste, particu-
larly in children, aﬀects appetite, reduces caloric
intake, induces weight loss, and worsens the
nutritional status (10, 11). Furthermore, TD may
cause anxiety, depression, and nutritional defi-
ciencies that may be dangerous, especially in
growing individuals (12).
The knowledge of TD features and prevalence
in children undergoing HSCT could be extremely
useful to define a targeted diet for these patients,
to improve their quality of life and also the out-
come of the entire treatment.
In a previous study, we validated a TST in a
group of 40 healthy children (12). Starting from
the knowledge of normal taste sensitivity, this
study aimed to determine the variability of TD in
children undergoing HSCT.
Materials and methods
Sample selection
This study was designed as a case-consecutive study.
Cases were identified as children consecutively enrolled in
the period January 2011 to January 2013 among the
patients attending the Paediatric Department of Spedali
Civili of Brescia that were candidates to HSCT for newly
diagnosed hemato-oncologic diseases. Children aged 3–
12 yr were considered eligible for the study. Patients with
mucosal lesions, history of food and drug allergies, and
chronic diseases (i.e., asthma, diabetes, coeliac disease)
were excluded. All children’s parents or caregivers gave
informed consent according to the recommendations of
the Declaration of Helsinki. Ethical approval for the
research was granted by the Ethic Committee (PRIN No.
200832LJ7P) of the Faculty of Medicine, University of
Brescia, Italy.
Taste evaluation
The TST, previously validated in another study (12), was
conducted in two phases: identification of threshold values
and identification of perceived stimulus intensity. Two pre-
viously calibrated examiners performed the TST in a quiet
room following a standardized protocol.
The test was performed using 16 sapid solutions at the
temperature of 24 °C (75.2 °F) with the four flavors
(sucrose, sodium chloride, citric acid, and quinine hydro-
chloride) at four diﬀerent concentrations (solution 1 was the
most dilute, solution 4 was the most concentrated)
(Table 1). Each clinician administered every solution once,
in addition to placebo solution (deionized water).
The patients tasted the solutions at the four concentra-
tions and were asked to identify their taste threshold, that
is, the lowest concentration at which each flavor could be
distinguished from water.
Samples were given in 2 mL solution, measured with spe-
cific pipettes, for at least 10 s. After each test, the subjects
were asked to rinse their mouth for 10 s with water. At the
end of the tasting phase, the results were reported on a chart
and then analyzed, starting from the lowest concentration
of the substance and proceeding towards the highest (from
1 to 4) to define the thresholds. To avoid bias due to the
modality, the sequence of the solutions administered was
randomly switched with every child following a predeter-
mined way: bitter, sour, sweet, salty; sour, sweet, bitter,
salty; sweet, salty, bitter, sour; salty, sour, bitter, sweet; and
so on. The children did not know in advance the type of
solution administered or the progressively increasing con-
centration. The intensity of the stimulus was evaluated
according to an analogical scale from 0 to 10 (where 0 is a
neutral stimulus, i.e., water, and 10 is the maximum inten-
sity of a flavor).
The same test protocol was used at diﬀerent time inter-
vals: before starting the conditioning therapy (T0), during
the conditioning therapy (T1) (two times), and every
three months (two times) after engraftment post-HSCT
(T2).
The conditioning regimens were categorized as “severe”
if they included TBI, included more than two drugs with
busulfan and one of the following: thiotepa or ale-
mtuzumab or etoposide. All other conditioning regimens
including busulfan for more than two days were classified
as “medium,” and the remaining were classified as “light”
(Table 2).
Table 1. Flavors and concentrations used for the test
Taste Flavor
Bitter Quinine hydrochloride
Salty Sodium chloride
Sweet Sucrose
Sour Citric acid
Concentration: SOL 1 0.000032 M, SOL 2 0.0001 M, SOL 3 0.00032 M, SOL 4
0.001 M.
Table 2. Classification of the conditioning regimens (1 = light conditioning
regimen; 2 = medium conditioning regimen; 3 = severe conditioning regimen)
(where A = antithymocyte globulin, B = busulphan, C = cyclophosphamide,
Ca = alemtuzumab, F = fludarabin, M = melphalan, T = thiotepa, V = vepe-
side and the numbers refer to the days each drug was used)
Conditioning regimens Classification n (total = 51)
B4C4 2 10
B4C4A2 2 10
B4C4A3 2 16
B4C4A6 2 1
B4C2Ca1T1 3 1
A1F5M1 1 1
A2F5M1 1 1
B4C4T1 3 1
B4C4T2 3 1
B4C1A1F5 2 1
B4C4Ca1T2 3 1
B4C2Ca1 3 1
C1A3F5 1 1
A2 1 1
A2 F5 1 1
F5 1 1
F5V2T2 3 1
F5Ca1T2M1 3 1
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Statistical methods and data analysis
Data were inserted into an ad hoc prepared Excel! work-
sheet. A descriptive analysis of mean values by ranks of
diﬀerent solutions in diﬀerent times was performed. Fur-
thermore, a generalized least squares for trend estimation of
summarized dose–response date for every solution was car-
ried out. A p-value < 0.05 was considered statistically sig-
nificant.
Results
Of 116 pediatric candidates to HSCT, a total of
51 children (29 female and 22 male, mean age
5.2 ! 0.7 yr) were considered eligible from the
research team (Fig. 1).
Results for threshold value means are repre-
sented in Table 3. Analysis by ranks was statisti-
cally significant, underlining a statistically
significant linear trend. The diﬀerence between
threshold value means at T0 and T1 was statisti-
cally significative (p < 0.01), as well as between
T1 and T2 (p < 0.01). The diﬀerence of threshold
value means between T0 and T2 was not statisti-
cally significant (p = 0.14).
Values for perceived intensity at the three inter-
val times resulted as follows: during conditioning
therapy, bitter, sour, and salty were recognized
only at the third concentration, and sweet at the
second concentration; at T2, every flavor was rec-
ognized in the most diluted solution, returning to
T0 values. The generalized least squares for trend
estimation of dose-response data for every solu-
tion type resulted statistically significant with an
higher response for the salt taste followed by sour
and sweet taste. (Table 4).
The increase in the severity of the conditioning
regimen was not statistically associated with
either an increase in the alteration of the thresh-
old value means or a decrease in the perceived
intensity of the stimulus.
ENROLLMENT
Assessed for eligibility (n=116)
Consecutive patients 
(n=61)
Excluded (n=55).  Not 
meeting inclusion 
criteria
Analyzed (n=51)
Excluded from analysis 
(not signed informed 
consent) (n=3)Excluded from analysis 
(worsening health 
condition) (n=6) Excluded from analysis  
(death) (n=1)
Fig. 1. Diagram demonstrating
the flow of participants through
each stage.
Table 3. Threshold values means for each flavor (bitter, sour, salt, sweet) at
time T0, T1, T2
SOL 1
(0.000032 M)
Mean (s.d.)
SOL 2
(0.0001 M)
Mean (s.d.)
SOL 3
(0.00032 M)
Mean (s.d.)
SOL 4
(0.001 M)
Mean (s.d.)
Bitter (z-test = "8.23, p < 0.01)
T0 2.24 (0.43) 5.00 (0.46) 7.24 (0.76) 9.75 (0.38)
T1 0.00 (–) 0.00 (–) 1.13 (0.54) 0.87 (0.52)
T2 0.37 (0.50) 3.13 (0.30) 4.50 (0.54) 6.00 (0.52)
Sour (z-test = "5.91, p < 0.01)
T0 5.00 (0.48) 2.24 (0.44) 4.75 (0.82) 8.25 (0.56)
T1 0.00 (–) 0.00 (–) 0.37 (0.50) 1.37 (0.49)
T2 0.00 (–) 1.75 (0.49) 2.75 (0.45) 6.63 (0.72)
Salt (z-test = "5.85, p < 0.01)
T0 1.00 (0.39) 3.50 (0.58) 5.75 (0.56) 8.00 (0.54)
T1 0.00 (–) 0.00 (–) 0.75 (0.44) 2.24 (0.46)
T2 0.00 (–) 0.63 (0.48) 2.63 (0.49) 5.50 (0.69)
Sweet (z-test = "5.90, p < 0.01)
T0 2.50 (0.63) 4.50 (0.69) 6.76 (0.83) 9.50 (0.58)
T1 0.00 (–) 0.24 (0.31) 3.24 (0.37) 3.37 (0.70)
T2 1.63 (0.52) 3.50 (0.54) 6.75 (0.76) 8.25 (0.54)
T0 = before starting conditioning therapy.
T1 = mean of the two measurements during conditioning therapy.
T2 = mean of the two measurements after engraftment.
[0 = neutral stimulus, 10 = maximum intensity of the flavor].
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Discussion
Taste alteration is a significant common problem
related to cancer therapy (8), and it is one of the
major causes of food aversion intake in children.
Literature studies focused on TD during HSCT
in children are hardly available. This study exam-
ines taste perception in children before, during,
and after conditioning therapy and attempts to
verify the presence and the duration of TD in this
type of pediatric population.
There are various mechanisms behind TD:
interference between toxic drugs and taste-recep-
tor cell turnover seem to play a major role. Che-
motherapy protocols use chemicals that interfere
with mitotic activity to destroy proliferating
cells. As taste receptors proliferate rapidly, the
renewal of these cells is stopped by antineoplas-
tic drugs until they remain active, with the con-
sequence that taste coding might be disrupted
during therapy; when chemotherapy stops, a
high proportion of taste cells rapidly renew and
make new contacts with nerve fibers (13, 14).
This can explain our finding that normal taste
returns about six months after conditioning
therapy (15). Chemotherapy can also have an
immediate eﬀect on taste because some drugs
pass into saliva, directly modifying taste percep-
tion (16).
The mechanisms determining TD may explain
the results of this study, which are slightly diﬀer-
ent than some previous reports, mostly involving
adults. Some studies showed that TD could take
from 1 to 3 yr from the end of therapy to nor-
malize (17), while we found a return to normal
values by six months after engraftment, with a
Gaussian trend. This discrepancy could be
explained by the more rapid taste receptors
regeneration in children compared to adults (18).
However, as regards the thresholds values, our
results are in agreement with other previously
published reports (19, 20), which found signifi-
cantly higher recognition threshold values for the
four tastes or at least an increase in the salty
threshold during chemotherapy (21). In the pres-
ent study, a significant diﬀerence between thresh-
old value means at T0 and T1 was found for all
flavors.
The conditioning regimens were categorized as
“severe,” “medium,” and “light” on the basis of
the type of drugs and the days each drug
was administered (Table 2). Among the chemo-
therapy drugs used, cyclophosphamide, melpha-
lan, thiotepa, and etoposide are known to be
associated with taste changes and to be also
highly emetogenic (10). However, no statistically
significant correlation between the severity of the
conditioning regimen and the alterations of the
threshold values or the intensity of the perceived
stimulus was found.
The problem of food intake in children with
oncologic problems is very common. Nausea and
vomiting play a potent role in the development
of food aversion. Moreover, food neophobia
(that is the avoidance of unfamiliar food) and
depression or anxieties due to preoccupied par-
ents’ coercion are further contributing factors
(10). The results of this study confirm that these
children can also temporarily suﬀer from altered
taste sensation. Our results strengthen the
hypothesis that taste alterations during cancer
therapies should be routinely assessed with the
use of an objective, easy to use and low cost
method (6), in order to identify factors that inter-
fere with the child’s food intake (10, 22). Further
studies are needed to identify possible medical
devices able to influence food perception. For
instance, oral zinc has been used to treat taste
and smell abnormalities in several alterated phys-
iologic states, including cancer-related TD (23).
The child’s individual food preferences and aver-
sion should be considered and combinations of
oral, enteral, and parenteral nutritional support
should be used.
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Table 4. Estimates of the generalized least-square regression for the four
tastes in the case group
Taste Coeff (s.e.) p-value
Bitter 0.04 (0.02) 0.03
Sour 0.03 (0.02) 0.02
Salt 0.06 (0.03) <0.01
Sweet 0.05 (0.02) 0.02
Generalized least squares regression: number of obs = 4.
Goodness-of-fit v22 = 6.93: p = 0.03.
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